Please wait while the formulary information is being retrieved.
BROVANA (ARFORMOTEROL TARTRATE)
- Bronchospasm prevention with COPD
- Prevention of bronchospasm with chronic bronchitis
- Prevention of bronchospasms with emphysema
15 mcg/2 mL solution for nebulization
- Inhale 2 milliliters (15 mcg) by inhalation route 2 times per day
Bronchospasm prevention with COPD
- Inhale 2 milliliters (15 mcg) by inhalation route 2 times per day
Prevention of bronchospasm with chronic bronchitis
- Inhale 2 milliliters (15 mcg) by inhalation route 2 times per day
Prevention of bronchospasms with emphysema
- Inhale 2 milliliters (15 mcg) by inhalation route 2 times per day
- None
Contraindicated
- bromocriptine
- cabergoline
- Cafergot
- Compound 347
- Cycloset
- D.h.e.45
- dihydroergotamine
- enflurane
- ergoloid
- Ergomar
- ergotamine tartrate
- ergotamine-caffeine
- Forane
- isoflurane
- methylergonovine
- Migergot
- Migranal
- Parlodel
- sevoflurane
- Sojourn
- Terrell
- Ultane
Severe
Moderate
- None
- Acutely deteriorating asthma
Contraindicated
- Congenital long QT syndrome
- Hypokalemia
- Prolonged QT interval
- Thyrotoxicosis
Severe
Moderate
- Chronic myocardial ischemia
- Diabetes mellitus
- Hypertension
- Seizure disorder
BROVANA (ARFORMOTEROL TARTRATE)
- Bronchospasm prevention with COPD
- Prevention of bronchospasm with chronic bronchitis
- Prevention of bronchospasms with emphysema
- Chest pain
- Peripheral edema
- Sinusitis
- Skin rash
- Back pain
- Cramps in legs
- Diarrhea
- Dyspnea
- Flu-like symptoms
- Pain
More Frequent
Severe
Less Severe
- Bronchitis
- Fever
- Hyperkalemia
- Leukocytosis
- Tremor
- Cramps
- General weakness
- Headache disorder
- Nervousness
- Pulmonary congestion
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abscess
- Acute cerebral infarction
- Acute myocardial infarction
- Anaphylaxis
- Angioedema
- Arteriosclerosis obliterans
- Atrial flutter
- Atrioventricular block
- Bone disease
- Cardiac arrhythmia
- Chronic heart failure
- Crystalluria
- Cystitis
- Dehydration
- Edema
- Gastritis
- Glaucoma
- Glycosuria
- Gout
- Hematuria
- Herpes simplex infection
- Herpes zoster
- Hyperglycemia
- Hyperlipidemia
- Hypertension
- Hypoglycemic disorder
- Hypokalemia
- Hypokinesia
- Hypotension
- Kidney stone
- Malaise
- Metabolic acidosis
- Neck stiffness
- Neoplasm
- Neoplasm of breast
- Paradoxical bronchospasm
- Paralysis
- Paroxysmal supraventricular tachycardia
- Periodontal infection
- Pyuria
- Tachycardia
Less Severe
- Agitation
- Arthralgias
- Arthritis
- Black tarry stools
- Constipation
- Dizziness
- Drowsy
- Dry skin
- Dyschromia
- Fatigue
- Insomnia
- Nausea
- Nocturia
- Oral paresthesia
- Palpitations
- Pelvic pain
- Skin hypertrophy
- Urticaria
- Visual changes
- Voice change
- Xerostomia
Contraindicated
None
Severe Precaution
Arformoterol
Safety and efficacy not established in pediatrics. Not approved for treatment of asthma.
- 1 Day – 18 Years
- Safety and efficacy not established in pediatrics. Not approved for treatment of asthma.
Management or Monitoring Precaution
None
Arformoterol
- Severity Level:
2
- Additional Notes: Insufficient human data
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Arformoterol
Insufficient human data; low plasma levels expected; mfr recommends caution
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data; low plasma levels expected; mfr recommends caution |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Arformoterol
Cardiovascular-Use caution in severe cardiovascular diseases, particularly coronary insufficiency, since beta-agonists increase heart rate and blood pressure. Endocrine-Use caution in poorly controlled hyperthyroidism or diabetes.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | N | Y |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Rarely, asthma patients using long-acting inhaled beta agonists (such as salmeterol) have had serious (sometimes fatal) asthma-related breathing problems. Because arformoterol is similar to salmeterol, it may also cause these problems. Therefore, patients with asthma should only be prescribed this drug if one long-term medication (such as inhaled corticosteroids) does not control breathing problems or if more than one long-term medication is clearly needed to control breathing problems.<br /><br />Arformoterol must not be used alone to treat asthma. Discuss the risks and benefits of treatment with this medication with your doctor.
| Bronchospasm prevention with COPD | |
| J44 | Other chronic obstructive pulmonary disease |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| Prevention of bronchospasm with chronic bronchitis | |
| J41 | Simple and mucopurulent chronic bronchitis |
| J41.0 | Simple chronic bronchitis |
| J41.1 | Mucopurulent chronic bronchitis |
| J41.8 | Mixed simple and mucopurulent chronic bronchitis |
| J42 | Unspecified chronic bronchitis |
| J44 | Other chronic obstructive pulmonary disease |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| Prevention of bronchospasms with emphysema | |
| J43 | Emphysema |
| J43.0 | Unilateral pulmonary emphysema [macleod's syndrome] |
| J43.1 | Panlobular emphysema |
| J43.2 | Centrilobular emphysema |
| J43.8 | Other emphysema |
| J43.9 | Emphysema, unspecified |
| J44 | Other chronic obstructive pulmonary disease |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| 0-9 | A-Z |
|---|---|
| J41 | Simple and mucopurulent chronic bronchitis |
| J41.0 | Simple chronic bronchitis |
| J41.1 | Mucopurulent chronic bronchitis |
| J41.8 | Mixed simple and mucopurulent chronic bronchitis |
| J42 | Unspecified chronic bronchitis |
| J43 | Emphysema |
| J43.0 | Unilateral pulmonary emphysema [macleod's syndrome] |
| J43.1 | Panlobular emphysema |
| J43.2 | Centrilobular emphysema |
| J43.8 | Other emphysema |
| J43.9 | Emphysema, unspecified |
| J44 | Other chronic obstructive pulmonary disease |
| J44 | Other chronic obstructive pulmonary disease |
| J44 | Other chronic obstructive pulmonary disease |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
Formulary Reference Tool